Diaceutics Plc (LON: DXRX) has released a trading update for the year ended 31 December 2019.
- The Group’s revenue is expected to be around £13.4 million as compared to £10.4 million for 2018.
- The adjusted EBITDA for the year to 31 December 2019 is expected to be above £2.1 million as compared to £1.5 million of 2018, well ahead of market expectations.
- Driven by key areas of geographic and technical focus for Diaceutics including Oncology, the overall precision medicine market is expected to double in size from 2018 to 2026.
- On 13th January 2020, at the time of writing, GMT 08:17 AM, DXRX shares were trading at GBX 117.50, up by 15.50 points or 15.20 % against the previous day closing price.
With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities.
Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?
Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.
We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.